[go: up one dir, main page]

PE20081785A1 - Derivados de ciclohexil-amida del acido aril carboxilico - Google Patents

Derivados de ciclohexil-amida del acido aril carboxilico

Info

Publication number
PE20081785A1
PE20081785A1 PE2008000326A PE2008000326A PE20081785A1 PE 20081785 A1 PE20081785 A1 PE 20081785A1 PE 2008000326 A PE2008000326 A PE 2008000326A PE 2008000326 A PE2008000326 A PE 2008000326A PE 20081785 A1 PE20081785 A1 PE 20081785A1
Authority
PE
Peru
Prior art keywords
cyclohexyl
hydroxy
amide derivatives
carboxyl acid
aryl carboxyl
Prior art date
Application number
PE2008000326A
Other languages
English (en)
Inventor
Rene Hersperger
Phillip Janser
Wolfgang Miltz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20081785A1 publication Critical patent/PE20081785A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE X ES CH2, NH; n ES 1-2; R ES CICLOALQUILO 3-18 ATOMOS DE CARBONO, HETEROCICLOALQUILO DE 3-18 ATOMOS DE CARBONO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: {4-HIDROXI-4-[2-((3S,4S)-4-HIDROXI-3-METIL-PIPERIDIN-1-IL)-ETIL]-CICLOHEXIL}-AMIDA DEL ACIDO 4-CICLOBUTIL-METOXI-1H-INDOL-2-CARBOXILICO; {4-HIDROXI-4-[2-((3S,4S)-4-HIDROXI-3-METIL-PIPERIDIN-1-IL)ETIL]CICLOHEXIL}-AMIDA DEL ACIDO 4-(4-OXO-4,5,6,7-TETRAHIDRO-BENZO-FURAN-3-IL-METOXI)-1H-INDOL-2-CARBOXILICO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE INFECCION POR VIH
PE2008000326A 2007-02-19 2008-02-15 Derivados de ciclohexil-amida del acido aril carboxilico PE20081785A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07102622 2007-02-19

Publications (1)

Publication Number Publication Date
PE20081785A1 true PE20081785A1 (es) 2009-01-12

Family

ID=38058317

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000326A PE20081785A1 (es) 2007-02-19 2008-02-15 Derivados de ciclohexil-amida del acido aril carboxilico

Country Status (35)

Country Link
US (1) US8354431B2 (es)
EP (1) EP2125782B1 (es)
JP (1) JP5180234B2 (es)
KR (1) KR101070984B1 (es)
CN (1) CN101605781B (es)
AR (1) AR065369A1 (es)
AT (1) ATE518854T1 (es)
AU (1) AU2008219317B2 (es)
BR (1) BRPI0807625A2 (es)
CA (1) CA2677565C (es)
CL (1) CL2008000497A1 (es)
CR (1) CR10957A (es)
CY (1) CY1111984T1 (es)
DK (1) DK2125782T3 (es)
EA (1) EA017000B1 (es)
EC (1) ECSP099584A (es)
ES (1) ES2371126T3 (es)
GT (1) GT200900226A (es)
HN (1) HN2009001607A (es)
HR (1) HRP20110793T1 (es)
IL (1) IL200191A (es)
MA (1) MA31206B1 (es)
MX (1) MX2009008145A (es)
MY (1) MY147487A (es)
NZ (1) NZ578663A (es)
PE (1) PE20081785A1 (es)
PL (1) PL2125782T3 (es)
PT (1) PT2125782E (es)
RS (1) RS51986B (es)
SI (1) SI2125782T1 (es)
TN (1) TN2009000345A1 (es)
TW (1) TW200848038A (es)
UA (1) UA97389C2 (es)
WO (1) WO2008101905A1 (es)
ZA (1) ZA200905160B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
CN119562806A (zh) 2022-05-25 2025-03-04 阿卡格拉医药公司 用于递送核酸的脂质纳米粒及其使用方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3532570B2 (ja) 1994-01-13 2004-05-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 哺乳類単球化学誘引物質タンパク質レセプター
EP1482042B1 (en) 1996-03-01 2009-04-15 Euroscreen S.A. Active and inactive CC-chemokine receptors and nucleic acid molecules encoding said receptor
EP0975749A2 (en) * 1996-05-28 2000-02-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6388055B1 (en) 1996-10-03 2002-05-14 Smithkline Beecham Corporation Mouse CC-CKR5 receptor polypeptide
AR008331A1 (es) 1997-01-23 1999-12-29 Smithkline Beecham Corp Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen
EP1039899A2 (en) * 1997-12-19 2000-10-04 Takeda Chemical Industries, Ltd. Pharmaceutical composition for antagonizing ccr5 comprising anilide derivative
US6312689B1 (en) * 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
CA2353635A1 (en) * 1998-12-21 2000-06-29 Takeda Chemical Industries, Ltd. Anilide derivative, production and use thereof
WO2001051077A1 (en) 2000-01-14 2001-07-19 The Government Of The United States Of Americarep Resented By The Secretary, Department Of Health And Human Services Methods of regulating il-12 production by administering ccr5 agonists and antagonists
AU2002212225A1 (en) 2000-09-08 2002-03-22 Micromet Ag Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
US20050004180A1 (en) 2001-10-03 2005-01-06 ZOU Dong Pyrrolidinone derivatives
AU2003289329A1 (en) * 2002-12-13 2004-07-09 Ono Pharmaceutical Co., Ltd. Antagonist and agonist binding to strong binding site of chemokine receptor
WO2004098638A1 (ja) * 2003-05-06 2004-11-18 Ono Pharmaceutical Co., Ltd. エフェクター細胞機能阻害剤
WO2005058234A2 (en) * 2003-12-11 2005-06-30 Yale University Methods and compositions relating to ccr5 antagonist, ifn-ϝ and il-13 induced inflammation
CN102344398B (zh) * 2003-12-18 2015-02-25 因赛特公司 作为趋化因子受体调控剂的3-环烷基氨基吡咯烷衍生物
GB0403038D0 (en) 2004-02-11 2004-03-17 Novartis Ag Organic compounds
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
BRPI0510665A (pt) * 2004-05-11 2007-12-04 Incyte Corp 3-(4-heteroarilcicloexilamino) ciclopentano-carboxiamidas como moduladores de receptores de quimiocinas
GB0412468D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US20070149557A1 (en) 2005-11-21 2007-06-28 Amgen Inc. CXCR3 antagonists
GB0525957D0 (en) 2005-12-21 2006-02-01 Astrazeneca Ab Methods
KR20090013827A (ko) 2006-06-12 2009-02-05 화이자 프로덕츠 인크. Ｈｉｖ 환자에서 면역 재구성을 증진시키고 기회 감염을 치료하기 위한 ｃｃｒ５ 길항제
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
CA2665808A1 (en) 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Ccr2 antagonists for treatment of fibrosis
TW200831497A (en) 2006-10-12 2008-08-01 Epix Delaware Inc Carboxamide compounds and their use
EP2099454A4 (en) 2006-11-17 2010-11-10 Abbott Lab AMINOPYRROLIDINES AS CHEMOKINE RECEPTOR ANTAGONISTS
EP2120928A2 (en) 2007-02-15 2009-11-25 Pfizer Limited Pharmaceutical compositions and methods for ccr5 antagonists
EP2150817A4 (en) 2007-04-30 2011-09-07 Progenics Pharm Inc PROCEDURE FOR REDUCING VIRUS LOAD IN HIV-1 INFECTED PATIENTS

Also Published As

Publication number Publication date
HK1138836A1 (en) 2010-09-03
EA200901085A1 (ru) 2010-02-26
PT2125782E (pt) 2011-11-17
ZA200905160B (en) 2010-05-26
CA2677565C (en) 2014-11-18
WO2008101905A1 (en) 2008-08-28
HN2009001607A (es) 2011-11-23
TW200848038A (en) 2008-12-16
JP5180234B2 (ja) 2013-04-10
ECSP099584A (es) 2009-09-29
AU2008219317A1 (en) 2008-08-28
CL2008000497A1 (es) 2008-08-29
CN101605781B (zh) 2014-08-13
CR10957A (es) 2009-09-01
AU2008219317B2 (en) 2011-09-08
UA97389C2 (en) 2012-02-10
JP2010519187A (ja) 2010-06-03
CA2677565A1 (en) 2008-08-28
KR101070984B1 (ko) 2011-10-06
IL200191A0 (en) 2010-04-15
US20100016361A1 (en) 2010-01-21
AR065369A1 (es) 2009-06-03
PL2125782T3 (pl) 2011-12-30
IL200191A (en) 2013-12-31
EP2125782B1 (en) 2011-08-03
DK2125782T3 (da) 2011-11-21
EA017000B1 (ru) 2012-09-28
MA31206B1 (fr) 2010-02-01
CN101605781A (zh) 2009-12-16
US8354431B2 (en) 2013-01-15
BRPI0807625A2 (pt) 2014-05-27
RS51986B (sr) 2012-02-29
SI2125782T1 (sl) 2011-12-30
NZ578663A (en) 2011-01-28
CY1111984T1 (el) 2015-11-04
TN2009000345A1 (en) 2010-12-31
MX2009008145A (es) 2009-08-12
MY147487A (en) 2012-12-14
KR20090103943A (ko) 2009-10-01
ES2371126T3 (es) 2011-12-27
EP2125782A1 (en) 2009-12-02
ATE518854T1 (de) 2011-08-15
HRP20110793T1 (hr) 2011-11-30
GT200900226A (es) 2010-07-02

Similar Documents

Publication Publication Date Title
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20040589A1 (es) Tiazolidinonas y su preparacion como medicamentos
PE20050121A1 (es) Acidos tienil-hidroxamicos, sustituidos referidos a la actividad enzimatica de la histona desacetilasa
PE20090183A1 (es) Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5
PE20130281A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
PE20090326A1 (es) Compuestos heterociclos como inhibidores de erk
PE20080186A1 (es) Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2
UY32547A (es) Piperidinas sustituidas como antagonistas de ccr3
PE20120620A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20080768A1 (es) Compuestos de isoindolina 5-sustituidos
UY32336A (es) Nuevos compuestos de acido 2-({ [(1Z)-1-2(2-amino-1,3-tiazol-4-il)-2-{ [(3S)-1-({ [5-hidroxi-4-oxo-1,4-dihidropiridin-2-il)-5-oxo-4-propil-4, 5 - dihidro - 1H - 1, 2, 4 - trialzol - 1 - il]sulfonil} carbamoil) -2 - oxazetidin -3 -il] amino} - 2 - oxoetiliden] amino} oxi) - 2 - metilpropanoico, composiciones farmacéuticas conteniendolos y aplicaciones.
PE20121522A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
PE20130009A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
DK2091948T3 (da) Nye inhibitorer af glutaminylcyclase
PE20081545A1 (es) Derivados de sulfonamida como inhibidores de acido graso sintasas
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20110367A1 (es) DERIVADOS DE 4-CIANO-4-FENIL-PIRROLIDIN-2-CARBOXAMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA INTERACCION p53-MDM2
CL2011000394A1 (es) Compuestos derivados de 1-hidroximetil-6,8-dioxa-biciclo[3.2.1]octano-2,3,4-triol, inhibidores de sglt2; cocristal que comprende a dicho compuesto y l-prolina o acido l-piroglutamico; composicion farmaceutica que los comprende; utiles para el tratamiento de la obesidad y diabetes de tipo 2.
PE20061353A1 (es) Compuestos de sulfonamida-tiazolopiridina como activadores de glucocinasa
PE20060569A1 (es) Compuestos de indol carbonilamino como inhibidores de la polimerasa ne5b del vhc
CO5700757A2 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20140966A1 (es) Quinazolincarboxamida azetidinas
MX2009003383A (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
PE20090243A1 (es) Compuestos de imidazol sustituido como inhibidores de renina

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed